Beyond Air® To Participate in BTIG’s 2023 Virtual Biotechnology Conference
August 01, 2023 16:05 ET
|
Beyond Air™
GARDEN CITY, N.Y., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on...
Beyond Air® Schedules First Fiscal Quarter 2024 Financial Results Conference Call and Webcast
July 24, 2023 16:05 ET
|
Beyond Air™
GARDEN CITY, N.Y., July 24, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on...
Beyond Air® Reports Financial Results for Fourth Quarter and Fiscal Year-End 2023
June 22, 2023 16:05 ET
|
Beyond Air™
Successfully completed phase 1 of U.S. commercial launch, with multiple hospitals contracted, and have initiated phase 2 of launch for LungFit® PH for the treatment of term and near-term neonates with...
Beyond Air® Secures up to $40 Million Debt Financing
June 15, 2023 16:10 ET
|
Beyond Air™
GARDEN CITY, N.Y., June 15, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...
Beyond Air® Licenses Commercial Rights to Selective Neuronal Nitric Oxide Synthase (nNOS) Inhibitors for the Treatment of Autism Spectrum Disorder from Hebrew University of Jerusalem
June 15, 2023 16:05 ET
|
Beyond Air™
Hebrew University’s preclinical results recently published in Advanced Science show a reversal of the molecular, synaptic and behavioral autism spectrum disorder (ASD) phenotypes Plan to initiate a...
Beyond Air® Schedules Fiscal Year End 2023 Financial Results Conference Call and Webcast
May 16, 2023 16:05 ET
|
Beyond Air™
GARDEN CITY, N.Y., May 16, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO)...
Beyond Cancer™ Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the American Association for Cancer Research (AACR) 2023 Annual Meeting
April 19, 2023 09:00 ET
|
Beyond Air™
Single and repeat dosing of UNO improves outcomes compared to checkpoint inhibitor monotherapy in the aggressive 4T1 breast cancer model mPD-L1 upregulation following UNO treatment helps to elucidate...
Beyond Air® Appoints Jeff Myers, M.D. Ph.D. as Chief Medical Officer
March 23, 2023 16:05 ET
|
Beyond Air™
GARDEN CITY, N.Y., March 23, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...
Beyond Cancer™ to Present Two Posters for Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2023 AACR Annual Meeting
March 14, 2023 16:35 ET
|
Beyond Air™
GARDEN CITY, N.Y. and HAMILTON, Bermuda, March 14, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric...
Beyond Air® Announces Participation at Two Upcoming Investor Conferences in March 2023
February 22, 2023 07:00 ET
|
Beyond Air™
GARDEN CITY, N.Y., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on...